Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.58 |
| ▸ | CASR | P41180 | 2/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30305027 | 0.85 | LOXL2 (0.55) | LOXL2CASRHRH4DPP4MTNR1A | |
| SCHEMBL27324837 | 0.85 | LOXL2 (0.59) | LOXL2CASRHRH4DPP4 | |
| SCHEMBL5365001 | 0.85 | LOXL2 (0.55) | LOXL2CASRHRH4DPP4MTNR1A | |
| SCHEMBL2074734 | 0.85 | LOXL2 (0.59) | LOXL2CASRHRH4DPP4 | |
| SCHEMBL5249054 | 0.85 | LOXL2 (0.55) | LOXL2CASRHRH4DPP4MTNR1A | |
| SCHEMBL14680760 | 0.83 | DPP4 (0.54) | LOXL2CASRHRH4DPP4MTNR1A | |
| SCHEMBL25146561 | 0.82 | HTR2A (0.45) | LOXL2CASRDPP4 | |
| SCHEMBL13921282 | 0.81 | LOXL2 (0.55) | LOXL2CASRHRH4DPP4MTNR1A | |
| SCHEMBL6254564 | 0.81 | LOXL2 (0.55) | LOXL2CASRHRH4MTNR1AMTNR1B | |
| SCHEMBL25973384 | 0.81 | LOXL2 (0.50) | LOXL2CASRHRH4DPP4MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118239981-A | Phosphonite ligand, catalyst and application thereof in hydroformylation reaction | 万华化学集团股份有限公司 | 2024-06-25 | — | — | CN | claimed |
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | AUBURN UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | AUBURN UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| CN-118239981-A | Phosphonite ligand, catalyst and application thereof in hydroformylation reaction | 万华化学集团股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2023245161-A2 | CATIONIC NONRIBOSOMAL LIPOPEPTIDES AND METHODS OF USE THEREOF | THE ROCKEFELLER UNIVERSITY (US) | 2023-12-21 | — | — | WO | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11759444-B2 | Methods for cancer and immunotherapy using prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759444-B2 | Methods for cancer and immunotherapy using prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-09-19 | — | — | US | disclosed |
| WO-2023116779-A1 | DIALKYNE COMPOUND AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023081832-A1 | METHODS FOR PREVENTING AND TREATING ACUTE KIDNEY INJURY | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20110117158-A1 | INHIBITION AND DISPERSION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-TRIAZOLE DERIVATIVES | MELANDER CHRISTIAN | 2011-05-19 | — | — | US | disclosed |
| US-7642265-B2 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7579479-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090170805-A1 | ANTI-MICROBIAL AGENTS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-07-02 | — | — | US | disclosed |
| US-20080227684-A1 | Small Molecule Inhibitors of PDZ Interactions | NONO INC. (CA) | 2008-09-18 | — | — | US | disclosed |
| US-7241780-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOLS-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
| EP-0411150-B1 | INDOLE DERIVATIVES, PREPARATION THEREOF, AND DRUG FOR PREVENTING AND TREATING NEPHRITIS CONTAINING SAME | OTSUKA PHARMA CO LTD (JP) | 1996-11-27 | — | — | EP | disclosed |
| US-5238938-A | Nephrosis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-24 | — | — | US | disclosed |
| EP-0411150-A1 | INDOLE DERIVATIVES, PREPARATION THEREOF, AND DRUG FOR PREVENTING AND TREATING NEPHRITIS CONTAINING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11759444-B2 | Methods for cancer and immunotherapy using prodrugs of glutamine analogs | ADORA2A, ADORA1, ADORA2B | LOXL2 2270/4885CASR 1326/4885HRH4 1280/4885 |
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | VIP, PTMS, IAPP | LOXL2 4704/4885CASR 3726/4885HRH4 1823/4885 |
| US-20110117158-A1 | INHIBITION AND DISPERSION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-TRIAZOLE DERIVATIVES | TFPI, O60361, TFPI2 | LOXL2 2376/4885CASR 2942/4885HRH4 2704/4885 |
| US-20080227684-A1 | Small Molecule Inhibitors of PDZ Interactions | PDLIM5, DAB2IP, PSD | LOXL2 4306/4885CASR 2577/4885HRH4 3510/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | LOXL2 881/4885CASR 1297/4885HRH4 3886/4885 |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, ACACA | LOXL2 2763/4885CASR 3814/4885HRH4 840/4885 |
| US-20090170805-A1 | ANTI-MICROBIAL AGENTS AND USES THEREOF | ACAT1, ACAT2, APEH | LOXL2 3547/4885CASR 1197/4885HRH4 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.